Adverse events84

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 84

Type	Event	Organ system	Group	Affected	At risk	Events
other	Diarrhoea	Gastrointestinal disorders	Balovaptan in Blinded Treatment Period	11	163	15
other	Diarrhoea	Gastrointestinal disorders	Placebo Blinded Treatment Period	14	158	15
other	Diarrhoea	Gastrointestinal disorders	Balovaptan in Open Label Extension Treatment Period	5	100	5
other	Diarrhoea	Gastrointestinal disorders	Placebo in Open Label Extension Treatment Period	4	97	4
other	Nasopharyngitis	Infections and infestations	Balovaptan in Blinded Treatment Period	14	163	14
other	Nasopharyngitis	Infections and infestations	Placebo Blinded Treatment Period	19	158	22
other	Nasopharyngitis	Infections and infestations	Balovaptan in Open Label Extension Treatment Period	7	100	10
other	Nasopharyngitis	Infections and infestations	Placebo in Open Label Extension Treatment Period	4	97	4
other	Upper respiratory tract infection	Infections and infestations	Balovaptan in Blinded Treatment Period	10	163	13
other	Upper respiratory tract infection	Infections and infestations	Placebo Blinded Treatment Period	9	158	11
other	Upper respiratory tract infection	Infections and infestations	Balovaptan in Open Label Extension Treatment Period	6	100	7
other	Upper respiratory tract infection	Infections and infestations	Placebo in Open Label Extension Treatment Period	7	97	11
other	Dizziness	Nervous system disorders	Balovaptan in Blinded Treatment Period	2	163	2
other	Dizziness	Nervous system disorders	Placebo Blinded Treatment Period	10	158	10
other	Dizziness	Nervous system disorders	Balovaptan in Open Label Extension Treatment Period	2	100	2
other	Dizziness	Nervous system disorders	Placebo in Open Label Extension Treatment Period	1	97	1
other	Headache	Nervous system disorders	Balovaptan in Blinded Treatment Period	8	163	13
other	Headache	Nervous system disorders	Placebo Blinded Treatment Period	7	158	9
other	Headache	Nervous system disorders	Balovaptan in Open Label Extension Treatment Period	5	100	5
other	Headache	Nervous system disorders	Placebo in Open Label Extension Treatment Period	10	97	17

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03504917/events

API reference For AI assistants

Adverse events84

Sources 3

Read this list from software.